Your browser version may not work well with NCBI's Web applications. More information here...
1: Curr Opin Investig Drugs. 2005 Jul;6(7):729-39.Links

Phenserine Axonyx.

Thatte U.

Department of Clinical Pharmacology, TN Medical College, Mumbai 400 008, India. mthatte@bom5.vsnl.net.in

The acetylcholinesterase inhibitor phenserine, the (-)-enantiomer of a phenylcarbamate derivative of physostigmine, is being developed as a potential therapy for Alzheimer's disease by Axonyx, under license from the National Institutes of Health/National Institute on Aging. In March 2005, Axonyx suspended patient recruitment for the ongoing phase III trials of phenserine, after the drug failed to meet the primary endpoints of the first of these trials, but in May 2005, the company was planning to reformulate the drug.

PMID: 16044670 [PubMed - indexed for MEDLINE]

Recent Activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on